UniProt P54760 · PDB · AlphaFold · Substrate: pEY · Clone: cytoplasmichigh-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Dasatinib | 99.3% | 0.7% | 87.97 | 0.699 |
| 2 | Bosutinib | 98.8% | 1.2% | 87.22 | 0.555 |
| 3 | Ponatinib | 98.5% | 1.6% | 78.23 | 0.534 |
| 4 | Repotrectinib | 98.2% | 1.8% | 84.21 | 0.608 |
| 5 | Ripretinib | 95.2% | 4.8% | 92.95 | 0.674 |
| 6 | Nilotinib | 94.6% | 5.4% | 96.49 | 0.765 |
| 7 | Tivozanib | 94.3% | 5.7% | 92.42 | 0.673 |
| 8 | Erdafitinib | 89.7% | 10.3% | 95.71 | 0.737 |
| 9 | Crizotinib | 88.9% | 11.1% | 91.39 | 0.581 |
| 10 | Vandetanib | 87.8% | 12.2% | 95.74 | 0.723 |
| 11 | Canertinib | 86.9% | 13.1% | 96.49 | 0.671 |
| 12 | Cabozantinib | 84.3% | 15.7% | 92.73 | 0.751 |
| 13 | Selpercatinib | 75.9% | 24.1% | 96.72 | 0.635 |
| 14 | Nintedanib | 72.2% | 27.8% | 90.23 | 0.608 |
| 15 | Dacomitinib | 71.4% | 28.6% | 97.99 | 0.664 |
| 16 | Gilteritinib | 67.1% | 32.9% | 88.97 | 0.506 |
| 17 | Alectinib | 66.9% | 33.1% | 95.49 | 0.651 |
| 18 | Fostamatinib | 64.4% | 35.6% | 96.74 | 0.613 |
| 19 | Pacritinib | 58.8% | 41.2% | 88.64 | 0.452 |
| 20 | Afatinib | 56.0% | 44.0% | 98.50 | 0.709 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 4.58
- Epithelial log2(TPM+1): 4.50
- Fold change: 0.08
- Status: No significant change
High-confidence drugs
- Nilotinib — inh 94.6% · KISS 45.14
- Dasatinib — inh 99.3% · KISS 41.48
- Erdafitinib — inh 89.7% · KISS 37.53
Selectivity landscape vs inhibition on EPHB4
Each point is one of the 92 approved drugs; color = inhibition % on EPHB4.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…